Ventyx Biosciences
Ventyx Halts TYK2 Inhibitor Despite Phase 2 Success, Stock Plummets 70%
Anika Sharma
Ventyx Biosciences discovered that even a seemingly successful clinical trial may not be enough to support a drug’s advancement, as ...
Ventyx reports positive phase 2 data for bowel disease drug, but fails to impress investors amid competition
Anika Sharma
Investors have shown skepticism toward Ventyx Biosciences’ attempt to challenge Bristol Myers Squibb and Pfizer in the ulcerative colitis market. ...
